{"id":"nicardipine-intravenous","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Flushing"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"3-8","effect":"Dizziness"},{"rate":"2-5","effect":"Nausea"},{"rate":"2-5","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1200326","moleculeType":"Small molecule","molecularWeight":"515.99"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nicardipine selectively blocks L-type calcium channels in vascular smooth muscle, preventing calcium-dependent contraction. This results in peripheral vasodilation and reduced systemic vascular resistance, leading to decreased blood pressure. The intravenous formulation allows for rapid onset and titration, making it useful for acute hypertensive episodes.","oneSentence":"Nicardipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation and reducing blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:57:05.458Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute hypertension management"},{"name":"Hypertensive emergency"},{"name":"Perioperative hypertension"}]},"trialDetails":[{"nctId":"NCT07364201","phase":"NA","title":"A Comparison of Nicardipine and Labetalol for Blood Pressure Control in Intensive Care Patients After Hemorrhagic Stroke Brain Surgery","status":"COMPLETED","sponsor":"Universitas Sumatera Utara","startDate":"2025-11-14","conditions":"Hemorrhagic Strokes, Postoperative Hypertension, Hemodynamic Instability","enrollment":30},{"nctId":"NCT07277283","phase":"PHASE4","title":"Nicardipine vs. Labetalol","status":"COMPLETED","sponsor":"Haseki Training and Research Hospital","startDate":"2025-02-01","conditions":"Acute Ischemic Stroke, Hypertensive Crisis","enrollment":34},{"nctId":"NCT07235514","phase":"NA","title":"Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-12-01","conditions":"Ischemic Stroke, Anterior Cerebral Circulation, General Anesthesia","enrollment":958},{"nctId":"NCT04352296","phase":"NA","title":"Effect of Individualized Versus Standard Bp Management During MT for Anterior Ischemic Stroke","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2021-03-08","conditions":"Acute Cerebrovascular Accident","enrollment":433},{"nctId":"NCT05155202","phase":"","title":"Clinical Relevance of Nicardipine Induced Hypoxemia in the Intensive Care Unit","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2021-11-15","conditions":"Hypoxemic Respiratory Failure, Side Effect, Hypertensive Emergency","enrollment":300},{"nctId":"NCT04116112","phase":"PHASE2","title":"Blood Pressure After Endovascular Stroke Therapy-II","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2020-01-17","conditions":"Acute Stroke, Endovascular Thrombectomy","enrollment":120},{"nctId":"NCT02116868","phase":"NA","title":"Pupillary Reflex Measurement to Guide Intraoperative Analgesia During Laparoscopic Surgery","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2014-03","conditions":"Scheduled Laparoscopic Surgery","enrollment":100},{"nctId":"NCT03761888","phase":"","title":"Nicardipine and Labetalol Effects on Cerebral Hemodynamics in Preeclampsia","status":"UNKNOWN","sponsor":"Hopital Antoine Beclere","startDate":"2018-11-29","conditions":"Preeclampsia Severe","enrollment":60},{"nctId":"NCT00415610","phase":"PHASE1","title":"Antihypertensive Treatment in Acute Cerebral Hemorrhage","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2005-07","conditions":"Intracerebral Hemorrhage, Hypertension, Stroke","enrollment":60},{"nctId":"NCT01176565","phase":"PHASE3","title":"Antihypertensive Treatment of Acute Cerebral Hemorrhage-II","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2011-05-15","conditions":"Intracerebral Hemorrhage","enrollment":1000},{"nctId":"NCT00765648","phase":"PHASE4","title":"Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2008-10","conditions":"Hypertensive Urgency","enrollment":226},{"nctId":"NCT02271191","phase":"PHASE4","title":"Effect of Nicardipine on Renal Function in Deliberate Hypotension","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-05","conditions":"Spinal Stenosis","enrollment":64},{"nctId":"NCT00803634","phase":"PHASE3","title":"Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2008-12","conditions":"Hypertension, Heart Failure","enrollment":117},{"nctId":"NCT00716079","phase":"NA","title":"The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial","status":"COMPLETED","sponsor":"The George Institute","startDate":"2008-09","conditions":"Intracerebral Hemorrhage, Stroke, Hypertension","enrollment":2839},{"nctId":"NCT01171911","phase":"PHASE4","title":"Comparison of Intravenous Injection of Calcium Antagonist and Beta-blockade on Endothelial Shear Stress of Coronary Artery","status":"UNKNOWN","sponsor":"Nanjing Medical University","startDate":"2010-10","conditions":"Acute Coronary Syndrome, Coronary Artery Disease","enrollment":200},{"nctId":"NCT00325793","phase":"PHASE4","title":"IV Double and Triple Concentrated Nicardipine for Stroke and ICH","status":"UNKNOWN","sponsor":"OSF Healthcare System","startDate":"2004-01","conditions":"Hypertension","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BLOOD GLUCOSE DECREASED"},{"count":1,"reaction":"DRUG ADMINISTRATION ERROR"},{"count":1,"reaction":"HYPOTENSION"},{"count":1,"reaction":"MALNUTRITION"},{"count":1,"reaction":"OVERDOSE"},{"count":1,"reaction":"OXYGEN SATURATION DECREASED"},{"count":1,"reaction":"POOR PERIPHERAL CIRCULATION"},{"count":1,"reaction":"RESPIRATORY ARREST"},{"count":1,"reaction":"RESUSCITATION"},{"count":1,"reaction":"SUDDEN DEATH"}],"_approvalHistory":[],"publicationCount":571,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nicardipine hydrochloride"],"phase":"marketed","status":"active","brandName":"nicardipine intravenous","genericName":"nicardipine intravenous","companyName":"Haseki Training and Research Hospital","companyId":"haseki-training-and-research-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nicardipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation and reducing blood pressure. Used for Acute hypertension management, Hypertensive emergency, Perioperative hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}